Tobias Toennis
A5004785417- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Cardiac electrophysiology and arrhythmias
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac pacing and defibrillation studies
- ECG Monitoring and Analysis
- Neuroscience and Neural Engineering
- Venous Thromboembolism Diagnosis and Management
Universität Hamburg
2021-2024
University Medical Center Hamburg-Eppendorf
2021-2024
German Centre for Cardiovascular Research
2023-2024
Device-detected atrial high-rate episodes (AHREs) are arrhythmias detected by implanted cardiac devices. AHREs resemble fibrillation but rare and brief. Whether the occurrence of in patients without (as documented on a conventional electrocardiogram [ECG]) justifies initiation anticoagulants is not known. Download PDF Research Summary. We conducted an event-driven, double-blind, double-dummy, randomized trial involving 65 years age or older who had lasting for at least 6 minutes one...
Abstract Aims Recent trial data demonstrate beneficial effects of active rhythm management in patients with atrial fibrillation (AF) and support the concept that a low arrhythmia burden is associated risk AF-related complications. The aim this document to summarize key outcomes 9th AFNET/EHRA Consensus Conference Atrial Fibrillation NETwork (AFNET) European Heart Rhythm Association (EHRA). Methods results Eighty-three international experts met Münster for 2 days September 2023. Key findings...
Abstract Background and Aims Patients with long atrial high-rate episodes (AHREs) ≥24 h stroke risk factors are often treated anticoagulation for prevention. Anticoagulation has never been compared no in these patients. Methods This secondary pre-specified analysis of the Non-vitamin K antagonist Oral anticoagulants patients Atrial High-rate (NOAH-AFNET 6) trial examined interactions between AHRE duration at baseline edoxaban placebo factors. The primary efficacy outcome was a composite...
Atrial high-rate episodes (AHRE) are atrial tachyarrhythmias detected by continuous rhythm monitoring pacemakers, defibrillators, or implantable cardiac monitors. occur in 10-30% of elderly patients without fibrillation. However, it remains unclear whether the presence these arrhythmias has therapeutic consequences. The AHRE increases risk stroke compared with AHRE. Oral anticoagulation would have potential to reduce but is also associated a rate major bleeding ∼2%/year. appears be lower...
Short and rare episodes of atrial fibrillation (AF) are commonly detected using implanted devices (device-detected AF) in patients with prior stroke or transient ischemic attack (TIA). The effectiveness safety oral anticoagulation TIA device-detected AF but no ECG-documented is unclear.
Subcutaneous implantable cardioverter-defibrillators (S-ICDs) have become established in preventing sudden cardiac death, with some advantages over transvenous defibrillator systems, including a lower incidence of lead failures. Despite technological advancements, S-ICD carriers may suffer from significant complications, such as premature battery depletion (PBD), that led to an advisory for nearly 40 000 patients. This multicentre study evaluated the PBD large set
Subcutaneous implantable cardioverter-defibrillators (S-ICDs) offer potentially distinct advantages over transvenous defibrillator systems. Recent randomized trials showed significantly lower lead failure rates than ICD. Still, S-ICDs remain associated with the risk of inappropriate shocks (IAS). While previous studies have reported varying causes IAS, this study explores a rare cause referred to as 'sense-B-noise.' It was recently described in case series, but its incidence has not been...